A Trial of Durvalumab (MEDI 4736) in Combination With Extended Neoadjuvant Regimens in Rectal Cancer

NCT04621370 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

48

Enrollment

OTHER

Sponsor class

Conditions

Rectal Cancer
Rectal Adenocarcinoma
Rectal Neoplasms

Interventions

DRUG: Durvalumab
DRUG: FOLFOX
RADIATION: Short Course Radiotherapy (Arm A)
RADIATION: Long course chemoradiation (Arm B)
DRUG: Capecitabine

Sponsor

Liz-Anne Lewsley

Collaborators

[object Object]
[object Object]
[object Object]